Acid Sphingomyelinase Deficiency (ASMD) is a rare inheritable disorder characterized by deficiency of the acid sphingomyelinase enzyme. It leads to an imbalance in sphingolipid metabolism and sphingomyelin accumulation in tissues and organs. There are two types of ASMD - Type A and Type B. Type A is characterized by onset in infancy and rapidly progressive neurodegeneration leading to death within the first two years. Type B has a later onset and slower disease progression with chronic liver disease and pulmonary complications being major clinical features. The current management focuses on symptomatic treatment and supportive care. Enzyme Replacement Therapy (using amine decarboxylase inhibitors) is the most advanced line of treatment being tested currently.

The acid sphingomyelinase deficiency (ASMD) market is estimated to be valued at USD 134.6 Mn in 2024 and is expected to reach USD 300 Mn by 2031, growing at a compound annual growth rate (CAGR) of 12.1% from 2024 to 2031.

The growing diagnosis of rare diseases and development of orphan drugs is expected to boost the demand for Acid Sphingomyelinase Deficiency (ASMD) Market treatment options globally. With better awareness, more patients are being diagnosed and this will expand the patient pool requiring customized therapies.

Get more insights on: Acid Sphingomyelinase Deficiency (ASMD) Market

Get this Report in Japanese Language: 酸性スフィンゴミエリナーゼ欠損症（ASMD）市場

Get this Report in Korean Language: 산성 스핑고미엘린 분해효소 결핍증(ASMD) 시장